Literature DB >> 21784144

Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances.

Tiago Vicente1, José P B Mota, Cristina Peixoto, Paula M Alves, Manuel J T Carrondo.   

Abstract

The advent of advanced therapies in the pharmaceutical industry has moved the spotlight into virus-like particles and viral vectors produced in cell culture holding great promise in a myriad of clinical targets, including cancer prophylaxis and treatment. Even though a couple of cases have reached the clinic, these products have yet to overcome a number of biological and technological challenges before broad utilization. Concerning the manufacturing processes, there is significant research focusing on the optimization of current cell culture systems and, more recently, on developing scalable downstream processes to generate material for pre-clinical and clinical trials. We review the current options for downstream processing of these complex biopharmaceuticals and underline current advances on knowledge-based toolboxes proposed for rational optimization of their processing. Rational tools developed to increase the yet scarce knowledge on the purification processes of complex biologicals are discussed as alternative to empirical, "black-boxed" based strategies classically used for process development. Innovative methodologies based on surface plasmon resonance, dynamic light scattering, scale-down high-throughput screening and mathematical modeling for supporting ion-exchange chromatography show great potential for a more efficient and cost-effective process design, optimization and equipment prototyping.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21784144     DOI: 10.1016/j.biotechadv.2011.07.004

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  9 in total

Review 1.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

Review 2.  Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Authors:  Mei Liu; Zhiyang Li; Jingjing Yang; Yanyun Jiang; Zhongsi Chen; Zeeshan Ali; Nongyue He; Zhifei Wang
Journal:  Cell Prolif       Date:  2016-06-16       Impact factor: 6.831

3.  A detection and quantification label-free tool to speed up downstream processing of model mucins.

Authors:  Sofia B Carvalho; Ana Sofia Moreira; Joana Gomes; Manuel J T Carrondo; David J Thornton; Paula M Alves; Julia Costa; Cristina Peixoto
Journal:  PLoS One       Date:  2018-01-09       Impact factor: 3.240

Review 4.  Virus-like particles: the new frontier of vaccines for animal viral infections.

Authors:  Elisa Crisci; Juan Bárcena; María Montoya
Journal:  Vet Immunol Immunopathol       Date:  2012-06-01       Impact factor: 2.046

Review 5.  In Vitro Assembly of Virus-Like Particles and Their Applications.

Authors:  Dinh To Le; Kristian M Müller
Journal:  Life (Basel)       Date:  2021-04-10

6.  Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

Authors:  Lisa A Santry; Thomas M McAusland; Leonardo Susta; Geoffrey A Wood; Pierre P Major; Jim J Petrik; Byram W Bridle; Sarah K Wootton
Journal:  Mol Ther Methods Clin Dev       Date:  2017-10-16       Impact factor: 6.698

Review 7.  Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.

Authors:  Guy-Alain Junter; Laurent Lebrun
Journal:  J Pharm Anal       Date:  2020-01-13

Review 8.  Virus-like particle-based vaccines for animal viral infections.

Authors:  Elisa Crisci; Juan Bárcena; María Montoya
Journal:  Inmunologia       Date:  2012-10-26

Review 9.  Construction and characterization of virus-like particles: a review.

Authors:  Andris Zeltins
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.